Finally, SGLT2 inhibitors may reduce the long-term risk of ischemic stroke via the reduction in incident AF, and it may reduce the risk of ICH complications when oral anticoagulants are used in CKD patients with AF via their potential effects on reducing the risk of hemorrhagic stroke. This evidence concerns the gene SLC5A2 and chronic kidney disease.